A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults

Inclusion Criteria

Subjects must have:

• Normal history and physical exam.
• HIV negativity by ELISA.
• CD4 count >= 400 cells/mm3.
• No clinically significant medical disease.
• No history of immunodeficiency, autoimmune disease, or use of immunosuppressive medication.
• No prior HIV vaccines.
• Classification in one of the eligible risk groups defined in the Disease Status field.

Eligible higher risk groups:

• Heterosexual teenagers and young adults (ages 16-28 permitted) who have attended a clinic for sexually transmitted diseases in the last 3 months or have higher risk sexual behavior.
• Homosexually active males who are practicing higher risk behavior (ages 18-60).
• Injection drug users active within the past 3 years (ages 18-60).
• Heterosexual partners of HIV seropositive individuals (ages 18-60).

Eligible lower risk groups:

• Homosexually active males who are practicing lower risk behavior (ages 18-60).
• Adult women and heterosexual adult men practicing lower risk sexual behavior (ages 18-60).

Exclusion Criteria

Prior Medication:

Excluded:

• Prior HIV vaccines.
• Prior immunosuppressive medications.
• Experimental agents within the past 30 days.
• AS PER AMENDMENT 07/02/97: Use of systemic steroids in the past month (for volunteers undergoing DTH testing).

AS PER AMENDMENT 07/02/97:

• History of eczema or allergic-type reactions to vaccines used in protocol 201 (for volunteers undergoing DTH testing).

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety